| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-143 | |
| Phytochemical name or plant extracts | Lupeol | |
| PMID | 35113358 | |
| Literature evidence | CONCLUSION: Our results indicate that lupeol could be considered as an anticancer agent and anticancer adjuvant in breast cancer-therapy. | |
| IUPAC name | (1R,3aR,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysen-9-ol | |
| Phytochemicals’ class or type of plant extracts | Triterpenoid | |
| Source of phytochemicals or plant Extracts | Elephantopus scaber | |
| Geographical availability | Andaman Is., Angola, Assam, Bangladesh, Cambodia, Cameroon, China South-Central, China Southeast, Comoros, East Himalaya, Hainan, India, Jawa, Laos, Madagascar, Malaya, Mozambique, Myanmar, Nansei-shoto, Nepal, Nicobar Is., Sri Lanka, Taiwan, Tanzania, Thailand, Vietnam, Zambia, Zaïre, Zimbabwe | |
| Plant parts | Leaves | |
| Other cancers | Breast cancer, Liver cancer, Stomach cancer, Prostate cancer, Skin cancer | |
| Target gene or protein | Caspase 3, MMP9, MMP2, COX-2, NF-κB p65, Bcl-2, | |
| Gene or Protein evidence | Lupeol individually and in combination with DOX up-regulated the expression of caspase-3. The proposed combination therapy synergized (3-4 fold) the down-regulation of MMP-9 expression in MCF-7 and MDA-MB-231 cells. The expression of COX-2, MMP-2, MMP-9 and NF-κB p65 levels was significantly down-regulated. These observations suggest that lupeol can inhibit the abilities of invasion of MDA-MB-231 cells by inhibiting the protein expression of COX-2, MMP-2 and MMP-9. The compound effectively downregulated Bcl-2 and Bcl-xL protein expressions, which directly contribute for the induction of MCF-7 cell apoptosis. | |
| Target pathways | In silico docking studies of Lupeol with MAPK pathway proteins- Raf-1, MEK & ERK. NF-κB signal pathway | |
| IC50 | 80 μM against MCF-7 | |
| Potency | Our results indicate that lupeol could be considered as an anticancer agent and anticancer adjuvant in breast cancer-therapy. The anticancer properties of lupeol attribute to its antiproliferative, antimigrative and apoptotic effects. | |
| Cell line/ mice model | MDA-MB-231, MCF-7, K 562, SW620, KATO-III, A-549, Hep-G2, Hep3B | |
| Additional information | Inhibition of Wnt signaling in cells with constitutive active Wnt/β-catenin results in loss of lupeol efficacy while inducing Wnt signaling sensitizes the cells to inhibitory effects of lupeol. | |
| PubChem ID | 259846 | |
| Additional PMIDs | 29859524 30549810 25364696 23836602 29397094 29720821 16119004 24522418 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:202958-1 | |
| Safety | NA |